BR112012012138A2 - composto, formas do mesmo, composições farmacêuticas do mesmo e métodos para preparação e uso - Google Patents

composto, formas do mesmo, composições farmacêuticas do mesmo e métodos para preparação e uso

Info

Publication number
BR112012012138A2
BR112012012138A2 BR112012012138A BR112012012138A BR112012012138A2 BR 112012012138 A2 BR112012012138 A2 BR 112012012138A2 BR 112012012138 A BR112012012138 A BR 112012012138A BR 112012012138 A BR112012012138 A BR 112012012138A BR 112012012138 A2 BR112012012138 A2 BR 112012012138A2
Authority
BR
Brazil
Prior art keywords
compound
methods
pharmaceutical compositions
preparation
forms
Prior art date
Application number
BR112012012138A
Other languages
English (en)
Other versions
BR112012012138B1 (pt
Inventor
Jia Hong
Shao Jiangyong
Su Wei-Guo
Zhang Weihan
Li Wenji
Sai Yang
Ren Yongxin
Cui Yumin
Tian Zhenping
Wu Zhenping
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44029398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012012138(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of BR112012012138A2 publication Critical patent/BR112012012138A2/pt
Publication of BR112012012138B1 publication Critical patent/BR112012012138B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

composto, certas novas formas do mesmo, composições farmacêuticas do mesmo e método para preparação e uso. composto de fórmula a e sais farmaceuticamente aceitáveis do mesmo e formas cristalina i e ii composto de fórmula a. além disso, métodos de preparação desses compostos, composições farmacêuticas compreendendo esses compostos e métodos para seus usos.
BR112012012138-3A 2009-11-23 2010-11-23 Composto, formas do mesmo, composições farmacêuticas do mesmo e métodos para preparação BR112012012138B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2009101992592A CN102070618B (zh) 2009-11-23 2009-11-23 一种化合物及其晶体
CN200910199259.2 2009-11-23
PCT/CN2010/078997 WO2011060746A1 (en) 2009-11-23 2010-11-23 Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use

Publications (2)

Publication Number Publication Date
BR112012012138A2 true BR112012012138A2 (pt) 2017-03-07
BR112012012138B1 BR112012012138B1 (pt) 2023-02-07

Family

ID=44029398

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012012138-3A BR112012012138B1 (pt) 2009-11-23 2010-11-23 Composto, formas do mesmo, composições farmacêuticas do mesmo e métodos para preparação

Country Status (18)

Country Link
US (2) US8658658B2 (pt)
EP (1) EP2504331B1 (pt)
JP (1) JP5758399B2 (pt)
KR (1) KR101513784B1 (pt)
CN (2) CN102070618B (pt)
AU (1) AU2010321366B2 (pt)
BR (1) BR112012012138B1 (pt)
CA (1) CA2781066C (pt)
DK (1) DK2504331T3 (pt)
ES (1) ES2529105T3 (pt)
IN (1) IN2012DN04868A (pt)
MX (1) MX2012005926A (pt)
MY (1) MY161749A (pt)
NZ (1) NZ600266A (pt)
PL (1) PL2504331T3 (pt)
PT (1) PT2504331E (pt)
RU (1) RU2507203C1 (pt)
WO (1) WO2011060746A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102070618B (zh) * 2009-11-23 2013-08-21 和记黄埔医药（上海）有限公司 一种化合物及其晶体
PT3157912T (pt) 2014-06-19 2019-06-04 Boehringer Ingelheim Animal Health Usa Inc Composições parasiticidas compreendendo derivados de indole, seus métodos e suas utilizações
CN105985326B (zh) * 2015-02-16 2020-04-14 上海宣创生物科技有限公司 嘧啶衍生物晶型ⅲ及其制备方法和用途
WO2016187767A1 (en) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Pharmaceutical compositions and use thereof
CN109963847A (zh) * 2016-11-18 2019-07-02 和记黄埔医药（上海）有限公司 治疗实体瘤的方法
JP2020164434A (ja) * 2019-03-28 2020-10-08 上野製薬株式会社 ２，６−ナフタレンビス（２−オキサゾリン）の製造方法
TW202143969A (zh) * 2020-03-09 2021-12-01 大陸商和記黃埔醫藥（上海）有限公司 抗ｐｄ－１抗體和多受體酪胺酸激酶抑制劑的藥物組合及其使用方法
WO2022220519A1 (ko) * 2021-04-12 2022-10-20 주식회사 미토이뮨테라퓨틱스 5-[(1,1-디옥시도-4-티오몰포리닐)메틸]-2-페닐-n-(테트라하이드로-2h-피란-4-일)-1h-인돌-7-아민의 신규 결정형

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005227997A1 (en) * 2004-03-30 2005-10-13 Arena Pharmaceuticals, Inc. Pyrimidine derivatives and methods of treatment related to the use thereof
US20090149467A1 (en) 2005-09-15 2009-06-11 Merck & Co., Inc. Tyrosine Kinase Inhibitors
ES2465673T3 (es) * 2007-04-16 2014-06-06 Hutchison Medipharma Enterprises Limited Derivados de pirimidina
CN101289444B (zh) * 2007-04-16 2012-01-04 和记黄埔医药（上海）有限公司 一种嘧啶衍生物及其医药用途
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
CN102070618B (zh) * 2009-11-23 2013-08-21 和记黄埔医药（上海）有限公司 一种化合物及其晶体

Also Published As

Publication number Publication date
KR20120097526A (ko) 2012-09-04
EP2504331B1 (en) 2014-11-12
CN102648194A (zh) 2012-08-22
CN102070618A (zh) 2011-05-25
EP2504331A4 (en) 2013-04-17
US8658658B2 (en) 2014-02-25
PL2504331T3 (pl) 2015-04-30
KR101513784B1 (ko) 2015-04-20
CA2781066A1 (en) 2011-05-26
CN102070618B (zh) 2013-08-21
MX2012005926A (es) 2012-11-23
PT2504331E (pt) 2015-02-20
RU2012126112A (ru) 2013-12-27
US8946249B2 (en) 2015-02-03
BR112012012138B1 (pt) 2023-02-07
ES2529105T3 (es) 2015-02-16
JP5758399B2 (ja) 2015-08-05
CA2781066C (en) 2014-09-16
IN2012DN04868A (pt) 2015-09-25
RU2507203C1 (ru) 2014-02-20
AU2010321366A8 (en) 2012-07-05
AU2010321366B2 (en) 2014-07-24
CN102648194B (zh) 2014-10-29
AU2010321366A1 (en) 2012-06-14
JP2013511475A (ja) 2013-04-04
DK2504331T3 (en) 2014-12-08
US20120270889A1 (en) 2012-10-25
NZ600266A (en) 2014-06-27
US20140200232A1 (en) 2014-07-17
MY161749A (en) 2017-05-15
WO2011060746A1 (en) 2011-05-26
EP2504331A1 (en) 2012-10-03

Similar Documents

Publication Publication Date Title
BR112012012138A2 (pt) composto, formas do mesmo, composições farmacêuticas do mesmo e métodos para preparação e uso
CU20110207A7 (es) Aril piridinas como inhibidoras de sintasa de aldosterona
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
UY32660A (es) Derivados aminobutricos sustituidos como inhibidores de neprilisina
ECSP14004812A (es) Triazolopiridinas sustituidas
CR20140032A (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como modulares de receptores de c5a
CU20120084A7 (es) Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación
UY33075A (es) Derivados de ciclohexano y usos de los mismos
UY33731A (es) ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep?
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
CU24272B1 (es) Derivados de tetrahidropirido-pirimidina como inhibidores de mek
CU20110217A7 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
UY33078A (es) Derivados de imidazoquinolina
ECSP13013011A (es) Triazolopiridinas
GEP20227397B (en) Inhibitors of influenza viruses replication
CO6650348A2 (es) Triazolopiridinas sustituidas
BRPI0913730A2 (pt) série de derivados de aminobenzoíla, sais farmaceuticamente aceitaveis, composições farmacêuticas, compostos, método para preparar os ditos compostos e usos
EA201300423A1 (ru) Кристаллический конъюгат налоксол-peg
BR112014001083B8 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
UY33348A (es) Compuestos de furopiridina y usos de los mismos
BR112014006643A2 (pt) compostos de imidazopiridina, composições e métodos de uso dos mesmos
CU20110108A7 (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos
BR112012006233B8 (pt) composto de fórmula i, composição farmacêutica e usos de um composto
TR200909784A1 (tr) Yeni sefdinir tuzları
BR112018015881A2 (pt) sal de maleato de agonista de tlr7, formas cristalinas, c, d e e do mesmo, métodos de preparação e usos de sal de maleato e formas cristalinas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/11/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.